Serum biomarkers are proteins generally detected in urine, blood, and other bodily fluids produced by malignant cells or in reaction to presence/absence of malignant cells. Preferably, biomarkers should have at least one or more than one of the following properties: prompt detection of cancer within high risk population, diagnosis of specific type of cancer, prediction in its growth, screen its treatment response, and detect early recurrence.
Scope of the Report:
The global serum cancer biomarkers market is projected to grow at a rapid pace in the next few years. Key drivers of the market are increase in the number of people suffering from different types of cancer and rise in the geriatric population. Increase in the cancer-afflicted population is anticipated to be another key driver of the market.
The worldwide market for Serum Cancer Biomarkers is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Serum Cancer Biomarkers in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Source Link – https://www.reportsandmarkets.com/sample-request/global-serum-cancer-biomarkers-market-2018-by-manufacturers-regions-type-and-application-forecast-to-2023Source: Click here